MIG (monokine induced by interferon-g) is a CXC chemokine ligand (CXCL9) that can potently inhibit angiogenesis, and displays thymus-dependent antitumor effects. The effectiveness of a treatment combining gene therapy with plasmid-borne MIG (pORF-MIG) and low-dose cisplatin chemotherapy was determined using colon carcinoma (CT26) and Lewis lung carcinoma (LL/2c) murine models. The program was carried out via intramuscular delivery of pORF-MIG at 100 mg/mouse twice a week for 4 weeks, and/or intraperitoneal delivery of cisplatin at 0.6 mg/kg/ mouse every 3 days for 48 days. Tumor volume and survival time were evaluated after treatment. CD31 immunohistochemical staining in tumor tissues and alginate capsule models in vivo was used to evaluate angiogenesis. Induction of apoptosis and cytotoxic T-lymphocyte (CTL) activity were also assessed. The combination of pORF-MIG and low-dose cisplatin produced significant antitumor activity, with complete tumor regression in 4/10 of CT26 colon carcinomas and 3/10 of LL/2c lung carcinomas, low vascularity, in alginate capsules, apparently degraded tumor microvessel density, and increased induction of apoptotic and CTL activities compared with either treatment alone. This study suggests that the combination of pORF-MIG plus cisplatin augments the inhibition of angiogenesis and the induction of apoptosis or CTL activity, all of which enhance antitumor activity. These findings may prove useful in further explorations of the application of combinatorial approaches to the treatment of solid tumors.
Introduction
The traditional troika of cancer therapies is comprised of chemotherapy as the first-line treatment for a wide variety of tumors, surgical intervention and radiation. However, dose-dependent toxicity and drug resistance greatly limit the therapeutic efficacy of chemotherapy. In recent years, several new chemotherapy regimes have emerged, including frequent protracted administration of low-dose conventional chemotherapeutic drugs on a metronomic schedule. [1] [2] [3] These regimes induce less toxicity, damage or kill the endothelial cells of tumor neovasculature, [4] [5] [6] and delay acquired resistance to chemotherapeutic drugs. 7, 8 Still, most of these rationally designed regimes are only mildly efficacious, especially when used in treating patients with advanced tumor diseases. Therefore, investigations in the oncology community have increasingly focused on the search for new paradigms and therapeutic approaches.
Angiogenesis (the generation of new blood vessels) is a key component for tumor growth and metastasis, and antiangiogenic therapy has become a potential antitumor strategy. [9] [10] [11] [12] Recently available antiangiogenic agents have received widespread attention and a number of new angiogenesis inhibitors are being explored in clinical trials. [10] [11] [12] Moreover, several lessons learned from early clinical trials in antiangiogenic therapy would seem to support a future role for antiangiogenic gene transfer strategies. 13 MIG (monokine induced by interferon-g (IFN-g)) is a member of the CXC chemokine subfamily, which lacks the characteristic proangiogenic ELR motif (ELR -). [14] [15] [16] MIG therefore functions as an angiostatic agent, and is known to promote tumor necrosis when administered intratumorally. 17 The MIG receptor, CXCR3, is exclusively expressed on T and NK cells after activation by IFN-g. 15 MIG also functions in vivo as a potent chemoattractant for tumor-infiltrating lymphocytes, 18 and activates peripheral blood lymphocytes, 14 as well as NK cells and TH 1 lymphocytes. 19 Therefore, MIG could be a potential candidate for antiangiogenic and immunomodulation therapy for tumor disease.
The utility of antiangiogenic therapy has been shown in many preclinical and clinical studies, but it is unlikely that this treatment modality alone will be sufficient to cure patients with significant metastatic diseases or high tumor burdens. However, the combination of an antiangiogenic strategy and low-dose metronomic chemotherapy has been shown to improve antitumor efficacy without a significant increase in host toxicity. 5, 6, 8 The rationale behind this approach is that combination therapy may improve antitumor effects by using agents that target different pathways.
This study explores the effect of a combined treatment regime that utilizes pORF-MIG gene therapy plus lowdose cisplatin, the most extensively used cytotoxic agent. The ability of this combined therapy to induce superior antitumor activity is evaluated.
Results
In vitro and in vivo expression and biological activity of murine MIG A cDNA clone containing full-length murine MIG sequence was inserted into an expression plasmid vector pORF-mcs (Invivogen, San Diego, CA, USA) that contains the EF-1a/HTLV hybrid promoter. In vitro protein production was confirmed in transfected COS-7-MIG cells by use of MIG antibodies in Western blotting analysis ( Figure 1a) . The in vitro biological activity of pORF-MIG was tested using a chemotaxis assay against murine activated spleen lymphocytes. The results suggest that conditioned medium from transfected COS-7-MIG cells attracted lymphocytes, compared with COS-7 cells transfected with an empty vector plasmid ( Figure  1b) . A sandwich enzyme-linked immunosorbent assay (ELISA) was used to determine in vivo MIG levels in the sera of a CT26 colon carcinoma tumor model after intramuscular delivery of pORF-MIG (12.5, 50 or 100 mg per injection), empty plasmid (pORF-mcs) or sterile phosphate-buffered saline (PBS). Circulating MIG levels were significantly elevated in mice that were given pORF-MIG at a dose of doses of 50 or 100 mg (Figure 1c ). These two dosages also simultaneously induced a better antitumor effect (data not shown).
Antitumor efficacy of the combination regime of pORF-MIG gene therapy plus low-dose cisplatin CT26 colon carcinomas and LL/2c lung carcinomas were established in two strains of immunocompetent mice, BALB/c and C57BL/6, to examine the effects of combination therapy. After tumor cells were subcutaneously inoculated for 7 days, the mice were randomly divided into four groups (10 mice/group) and subjected to one of the following treatments: pORF-MIG plus lowdose cisplatin, pORF-MIG alone, low-dose cisplatin alone or sterile PBS. The results showed that pORF-MIG or low-dose cisplatin alone inhibited tumor growth to a certain extent, but there was no complete tumor regression in the two groups. However, combined treatment with pORF-MIG and low-dose cisplatin resulted in retarded tumor progression. There were 11-and 13-day delays in the time needed for tumor growth to reach a volume of 900 mm 3 compared with sterile PBS treatments in CT26 and LL/2c carcinomas. The combined treatment also produced a complete regression of established tumors in 40% (4/10) of CT26 colon carcinomas and in 30% (3/10) of LL/2c lung carcinomas (both Po0.05) (Figures 2a and b) . The average lifespan of PBS-treated mice with CT26 or LL/2c tumor loads was 28.5 days (CT26) and 30.6 days (LL/2c), 36.5 days and 37.8 days with pORF-MIG alone, and 33.5 days and 34.6 days with only low-dose cisplatin. In contrast, the combined treatment of pORF-MIG plus low-dose cisplatin resulted in a significant increase in lifespan to 465 days in 70% of all experimental animals, with an average survival time of up to 69 days in the two tumor models (Po0.05, by log-rank test) (Figures 2c and d) .
Inhibition of tumor angiogenesis
Evidence for inhibition of angiogenesis was first found in the alginate-encapsulated tumor cell assay (Figure 3) . The vascular plexus of the tumor in the PBS group formed a ladder-like pattern (Figure 3a ) that was richly morphological and irregular. Whereas tumors treated with pORF-MIG or low-cisplatin alone exhibited relatively little vascularity (Figures 3c and b) , the combined therapy group displayed the least amount of vascularization (Figure 3d ). Angiogenesis of implanted alginate beads was quantitated by measuring the uptake of 
Induction of apoptosis in tumor tissues
The TdT-mediated dUTP nick end labeling (TUNEL) assay was performed on frozen sections of LL/2c tumor tissues obtained from mice after treatment cessation for a determination of the apoptotic index. The result showed that treatment with pORF-MIG or cisplatin alone (Figures 5b and c) affected the apoptotic rate of tumor cells when compared with PBS ( Figure 5c) ; however, the density of apoptotic cancer cells increased after the combined therapy ( Figure 5a ). The apoptotic index, calculated as a ratio of the apoptotic cell number to the total cell number in each field, showed a significantly augmented effect in the increased amount of cell apoptosis ( Figure 5c ). This finding suggests that increased apoptosis of the tumor cells is partially responsible for the enhanced antitumor activity of combination therapy.
Effect of combination therapy on cytotoxic T-lymphocyte activities
Determination of cytotoxic T-lymphocyte (CTL) activity provided evidence for the involvement of an immunological mechanism in the antitumor effect of the combination therapy. Purified spleen T lymphocytes isolated from BALB/c mice 3 days after cessation of therapy with pORF-MIG or pORF-MIG plus low-dose cisplatin specifically reduced lysis of CT26 tumor target cells by 12.27 and 20.47%, respectively. In contrast, less than 3% of target cell lysis was achieved by spleen T lymphocytes obtained from mice treated with low-dose cisplatin or PBS ( Figure 6 ) (Po0.05).
Discussion
Several observations have been made in the present study concerning a combination therapy for tumor treatment. The regime incorporated the use of gene therapy, via intramuscular delivery of plasmid DNA encoding MIG (pORF-MIG), and low-dose cisplatin chemotherapy in CT26 and LL/2c murine models. Intramuscular injection of pORF-MIG resulted in significant antitumor effects. The combination of pORF-MIG plus low-dose cisplatin enhanced the inhibition of tumor growth and even led to tumor regression. Furthermore, the augmented antitumor activity of this combination therapy resulted from a great diminishment of tumor Antitumor efficacy of MIG gene therapy plus cisplatin R Zhang et al vascularity and increased induction of apoptosis and CTL activities. Most importantly, the enhancement of tumor activity occurred without an ensuing increase in host toxicity or signs of acquired drug resistance during the course of treatment. Angiogenesis is a complex multistep process that is tightly regulated by many positive and negative factors. 9, 10 Several lines of direct and indirect evidence indicate that the growth and persistence of solid tumors and their metastasis are angiogenesis dependent. 20 As a strategy for cancer therapy, antiangiogenic therapy attempts to stop new vessels from forming around a tumor and to break up the existing network of abnormal capillaries that feed the cancerous mass. 20 Antiangiogenic gene therapy strategies usually involve the constitutive expression of an antiangiogenic protein. Therefore, it is expected to be more effective than a gene therapy approach that directly targets a tumor cell, for the latter requires the efficient transduction of the tumor cells themselves, and might quickly develop an escape mechanism. 13 Moreover, constitutive expression of an antiangiogenic protein, even at lower concentrations, may be more effective than the intermittent peaks associated with repeated delivery of a recombinant protein in a mouse model. 21 Several candidate genes, such as Thrombospondin-1, 22 Interleukin (IL)-12, 23 CXC chemokines platelet factor-4 (PF4), 24 Interferon-inducible protein-10 (IP-10), have been tested in preclincal trails. 25 MIG, monokine induced by IFN-g, belongs to the CXC chemokine subfamily. The absence of the ELR motif in MIG is the source of its potent angiostatic and antineoplasm properties in mouse tumor models. 16, 19 It has been shown to produce increased tumor necrosis in a model of Burkitt's lymphomas in athymic mice, 17 and to inhibit tumorigenesis via inhibition of tumor-derived angiogenesis. 26 Studies have also indicated that the antitumor activity of IL-12 is associated with the induction of IFN-g and the subsequent induction of the ELR -CXC chemokines MIG and IP-10, which in turn leads to a reduction of tumor-derived neovascularization. 
The exact mechanism by which MIG inhibits angiogenesis has not been fully elucidated. It is known that the chemokine can bind the CXCR3 receptor that is expressed on endothelial surfaces, which may subsequently inhibit cell migration to tumors. 28 MIG has the immunological properties of chemotaxis and activation of T and NK cells through binding of the CXCR3 receptor on cell sufaces. 29, 30 In this study, we demonstrate that intramuscular injection of plasmid-encoded MIG increases circulating levels of MIG and stimulates antitumor activity.
The antitumor strategy in this study was designed to combine pORF-MIG gene therapy and the metronomic delivery of the cytotoxic drug cisplatin. Metronomic chemotherapy is a new regime, which is considered much more effective than traditional chemotherapy in damaging or killing genetically stable, endothelial cells in newly formed tumor neovasculature. The extended rest periods that are required during traditional chemotherapy, to allow patients to recover from associated toxicity, also provide time for the recovery of tumor tissue endothelium. 2, 6 An additional rationale behind metronomic low-dose chemotherapy is that dividing endothelial cells in newly forming tumor vessels are genetically stable and do not easily develop gene mutations, such as p53 mutations. Therefore, they are more susceptible to the apoptotic effects of cytotoxic agents than are tumor cells. 31 This observation is consistent with other types of normal dividing cells, such as hair follicles, bone marrow or gut mucosal cells. 4 Recently, a body of direct and indirect evidence has demonstrated that combined treatments with antiangiogenic biotherapy plus low-dose chemotherapy suppress tumor growth more effectively than either treatment alone, even when the tested tumors have been acquired drug resistance before therapy, and the occurrence of Antitumor efficacy of MIG gene therapy plus cisplatin R Zhang et al side effects are also considerably low. 5, 6, 32, 33 The fact that the combined agents target a number of different or synergistic pathways may be the principal reason for the improvement of antitumor effectiveness. The findings of this study reveal that combined treatment with pORF-MIG plus low-dose cisplatin achieves significant antitumor efficacy with tumor regression in two tumor models, and prolongs survival of tumor-bearing mice when compared with either treatment alone. The mechanism is primarily based on the enhanced inhibition of tumor angiogenensis and augmented induction of apodosis, which were confirmed by the alginate assay and CD31 and TUNEL immunostaining of tumor sections.
Because the induction of apoptosis by cytotoxic agents is selectively enhanced when combined with an angiogenesis inhibitor, the tumor cells supported by the microvessel subsequently undergo extensive apoptosis. This outcome is also described and explained in previous reports, 34, 35 which demonstrate that cytotoxic agents induce apoptosis in tumor cells as well as in endothelial cells. Although cytotoxic drug delivery on a low-dose antiangiogenic schedule may effectively inhibit tumor growth, 36 it is still difficult to explain the exact mechanisms of apoptotic generation. One possibility is that the delivery of antiangiogenic agents decreases the diffusion of oxygen and nutrients, and results in tumor cells undergoing apoptosis. Another scenario might be concomitant paracrine release of apoptotic-inducing factors. Our data suggest that induction of cell apoptosis, the main outcome of chemotherapy administered on an MTD schedule, plays an important role in the suppression of tumor growth in the present combination strategy. In this regard, these results may provide a paradigm for the combination of low-dose chemotherapeutic drugs and other antiangiogenic gene therapy Antitumor efficacy of MIG gene therapy plus cisplatin R Zhang et al agents: attainment of the same curative effects as conventional chemotherapeutic schedules without the systemic toxic side effects. The immunological mechanism is further explored in this combined antitumor strategy. MIG activates both CD8 + and CD4 + T lymphocytes, and depresses tumor growth not only by antiangiogenesis but also by induction of special CTL responses. 19, 37 Recent reports suggest that some conventional cytotoxic drugs administered on a low-dose schema, thereby potentially avoiding the immunosuppressive effects of these drugs, can be exploited for a strategy of reduction-specific CTL response in mice. When combined with an immunopotentiating agent, the induction efficacy of the CTL response is dramatically enhanced over either treatment alone. 38 It may be the reason that combined treatment with pORF-MIG plus metronomic cisplatin induced more CTL activity in homogeneous tumor cells than either treatment alone.
In summary, these studies suggest that the combination of pORF-MIG gene therapy and low-dose chemotherapy is more effective in the treatment of experimental murine carcinomas, apparently prolonging the lifespan with minimal side effects. The combined schedule may be well suited to clinical cancer management. However, more studies are needed to explore gene therapy vectors, optimal drug dosages and scheduling characteristics of these tumors.
Materials and methods

Construction of an expression plasmid encoding murine MIG
The nucleotide sequence encoding the mature region of murine MIG cDNA was amplified from pBLAST-mMIG (Invivogen) and cloned into expression vector plasmid pORF-mcs (Invivogen), which contains the EF-1a/HTLV hybrid promoter. The resultant recombinant plasmid was named pORF-MIG. pORF-MIG and pORF-mcs were purified by two rounds of passage over endo-free columns (Qiagen, Chatsworth, CA, USA) as reported previously, 39 and was subsequently used for transfection of COS-7 cells and in antitumor treatments.
Western blot analysis
COS-7 kidney cells were transfected with pORF-MIG and the pORF-mcs using a lipofectin transfection kit (Invitrogen, San Diego, CA, USA). 40 After 72 h, COS-7 and COS-7-MIG cells were harvested for the detection of protein expression. Western blot analysis was performed with total protein from cell lysate homogenates. Briefly, conditioned media were separated on Tricine-PAGE gels, which were electroblotted with Sartoblot onto a PVDF membrane. The membrane blots were blocked at 41C in 5% nonfat dry milk, washed and probed with murine MIG antibody (R&D Systems Inc., Minneapolis, MN, USA) at 1/200 dilution. The blots were then washed and incubated with biotinylated secondary antibody (biotinylated rabbit anti-goat IgG), followed by transfer to Vectastain ABC (Vector Laboratories, Burlingame, CA, USA). 39 
In vitro chemotaxis assay
Cell culture supernatants were harvested from COS-7 and COS-7-MIG kidney cells after 72 h of fetal bovine serum deprivation. 37 Spleen lymphocyte migration was assayed in a 96-well Boyden chemotaxis microchamber (Neuroprobe, Gaithersburg, MD, USA). The lower wells of the chamber were filled with 50 ml of supernatants obtained as described above. A polycarbonate membrane with a pore size of 5 mm was placed above the wells and 50 ml of cell suspension (5 Â 10 6 spleen lymphocytes/ml migration medium) was added to the upper compartment of the migration chamber and incubated for 4 h at 371C in a humidified CO 2 incubator. Cells that migrated through the polycarbonate membrane were harvested from the lower chamber and counted under a microscope. Results were expressed as the mean value of triplicates7s.d. The assay was repeated three times with a variability of o10%.
Enzyme-linked immunosorbent assay determination of recombinant MIG
The level of recombinant MIG in serum after intramuscular delivery of pORF-MIG plasmid was determined by a sandwich ELISA assay, as described previously, with slight modifications. 40, 41 Briefly, a 96-well microtiter plate (Falcon) was coated with goat anti-mouse MIG capture antibody (R&D Systems Inc.) overnight at 41C. The next day, the plate was blocked with bovine serum albumin, and 100 ml of mice sera or standard was added in appropriate diluents. The detection antibody was a biotinylated anti-mouse CXCL9/MIG antibody (R&D Systems Inc.). The assay procedure was performed according to the ELISA protocol provided by R&D Systems Inc. The optical density of each well was determined within 30 min using a microplate reader set at 450 nm. Serial twofold dilutions of recombinant MIG were used as a standard. The assay was repeated three times.
Animal experiment
The CT26 colon carcinoma (CT26) model and Lewis lung carcinoma (LL/2c) model were established in BALB/c and C57BL/6 female mice at 6-8 weeks of age. After tumors had grown for 7 days, the mice were randomly divided into four groups (10 mice/group) for treatments according to similarly described procedures. 42 . At the end of the experiment, the mice were killed and their tumor tissues were collected for subsequent histological experiments (see below). All studies involving mice were approved by the Institute's Animal Care and Use Committee.
In vivo alginate-encapsulated tumor cell assay
Alginate-encapsulated tumor cell assays were performed as described previously. 44, 45 Briefly, CT26 cells were resuspended in a 1.5% solution of sodium alginate and added dropwise to a swirling 371C solution of 250 mM calcium chloride. Alginate beads were formed, containing approximately 1 Â 10 5 tumor cells per bead. BALB/c mice were then anesthetized, and four beads were subcutaneouly implanted into an incision made on the dorsal side. Incisions were closed with surgical clamps. The same drug treatments were started 24 h after bead implantations. After 14 days, the mice were injected intravenously with 100 ml of a 100 mg/kg FITC-dextran solution (Sigma, St Louis, MO, USA). Beads were surgically removed and the FITC-dextran was quantified against a standard curve.
Immunohistochemical analyses
Sections of tumor tissues were processed and stained with rat anti-mouse CD31 antibody by an avidin-biotinperoxidase method using the VECTASTAIN Elite ABC KIT (Vector Laboratories), following the manufacturer's instructions. 46 Vessel density was determined by counting the number of microvessels per high-power field, as described previously. 47 
Quantitative assessment of apoptosis
Cell apoptosis analysis used a TUNEL assay according to the manufacturer's instructions (In situ Cell Death Detection Kit, AP, Roche Diagnostics, Mannheim, Germany). Slides were imaged in a Nikon (ECLIPSE E600) fluorescence microscope at Â 200 magnification. Digital images were acquired and processed using Adobe Photoshop (Adobe Inc., Mountain View, CA, USA), and were quantified as described previously. 42 
Cytotoxicity assay
A 4-h 51 Cr release assay was performed as described previously. 48, 49 Briefly, spleen T lymphocytes obtained from BALB/c mice 3 days after cessation of treatment were treated with ammonium chloride-potassium lysing buffer to deplete erythrocytes. A T-cell-enriched fraction was prepared by further incubation of these splenocytes in complete medium for 90 min. Non-adherent cells were gently removed and incubated on nylon wool columns while recovered T cells were washed. NK cells were also depleted using NK1.1 mAb (clone DX5, BD PharMingen, San Diego, CA, USA) as described previously. 49 CT26 cells served as target cells. A total of 100 ml of effector cells and 51 Cr-labeled target cells were assigned at different E:T ratios to each well of a microtiter plate, and incubated for 4 h at 371C. Samples were then harvested, and activity was calculated by the formula [(E-S)/(T-S)] Â 100, with E being the average experimental release, S the average spontaneous release and T the average total release. The spontaneous 51 Cr release usually did not exceed 20% of the total isotope count.
Statistical analysis
Data were assayed by analysis of variance and the Student's t-test. Kaplan-Meier curves were established for each group of animals, and survival was compared by means of the log-rank test. Differences between means or ranks, as appropriate, were considered significant when yielding a P-value o0.05.
